CNAT Stock Just Plunged 60%: Should Investors Be Worried?
CNAT stock plunged more than 60% Tuesday. Why? The significant drop comes after Conatus Pharmaceuticals (NASDAQ:CNAT) said twenty-four hours prior that it will be implementing a restructuring plan due to its liver disease drug failing ... [Read]
Conatus Pharmaceuticals Shares Dive After Failed Clinical Trial
Shares of Conatus Pharmaceuticals (Nasdaq:CNAT) have taken a dive, dropping over 30%, after releasing the results from their Phase 2b clinical trial. The POLT-HCV-SVR clinical trial, which studied emiscaran in liver transplant patients with fibrosis ... [Read]